The USPTO sends a Notice of Allowance to Titan Pharmaceuticals (TTNP +3.9%) for a patent covering the sustained release of dopamine using the company's proprietary long-term drug delivery technology, ProNeura. "Implantable Polymeric Device for Sustained Release of a Dopamine Agonist" provides IP protection for Titan's ProNeura program for Parkinson's disease and carries a term to at least 2024.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs